| ||||||||||||||
|
|
|||||||||||||
Department of General Anesthesiology, The Cleveland Clinic Foundation, Cleveland, Ohio; and *Mayo Clinic, Rochester, Minnesota
Address correspondence and reprint requests to Jonathan H. Waters, MD, The Cleveland Clinic Foundation, Department of General Anesthesiology, E-31, 9500 Euclid Avenue, Cleveland, OH 44195. Address e-mail to Watersj{at}ccf.org
IMPLICATIONS: We describe a patient who experienced intraoperative bleeding after being treated with platelet receptor glycoprotein IIb/IIIa antagonist eptifibatide. We used Sonoclot® and Thrombelastograph® to monitor antiplatelet effects of eptifibatide.
This article has been cited by other articles:
![]() |
M. T. Ganter and C. K. Hofer Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation Devices Anesth. Analg., May 1, 2008; 106(5): 1366 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Tucci, M. T. Ganter, C. R. Hamiel, R. Klaghofer, A. Zollinger, and C. K. Hofer Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1314 - 1322. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Katori, F. Szlam, J. H. Levy, and K. A. Tanaka A Novel Method to Assess Platelet Inhibition by Eptifibatide with Thrombelastograph(R) Anesth. Analg., December 1, 2004; 99(6): 1794 - 1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Tanaka, N. Katori, F. Szlam, N. Sato, A. B. Kelly, and J. H. Levy Effects of tirofiban on haemostatic activation in vitro Br. J. Anaesth., August 1, 2004; 93(2): 263 - 269. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chun, B. A. Orser, and M. Madan Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist Anesth. Analg., October 1, 2002; 95(4): 879 - 888. [Full Text] [PDF] |
||||
|